Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein ; volume:22 ; number:1 ; day:14 ; month:3 ; year:2024 ; pages:1-13 ; date:12.2024
BMC biology ; 22, Heft 1 (14.3.2024), 1-13, 12.2024
- Creator
-
Anderson, Trevor S.
McCormick, Amanda L.
Smith, Savanna L.
Lowe, Devin B.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12915-024-01860-x
- URN
-
urn:nbn:de:101:1-2405162120075.637381857289
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Anderson, Trevor S.
- McCormick, Amanda L.
- Smith, Savanna L.
- Lowe, Devin B.
- SpringerLink (Online service)
Other Objects (12)
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
Antibody Drug Conjugates
Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
FLT3 specific antibody-drug-conjugate for the treatment of acute myeloid leukemia
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
Antibody Drug Conjugates
Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
FLT3 specific antibody-drug-conjugate for the treatment of acute myeloid leukemia
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
Antibody Drug Conjugates
Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
FLT3 specific antibody-drug-conjugate for the treatment of acute myeloid leukemia
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin